S3 Fig

Forest plot of comparison between SLDMD and placebo at 12 months (A), FLDMD and placebo at 12 months (B), SLDMD and placebo at 24 months (C), FLDMD and placebo at 24 months (D).

(٨)
Ų		J

	SLDMD PCB							Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
AFFIRM	-0.56	0.97	606	-0.4	1.02	296	25.7%	-0.16 [-0.30, -0.02]	_		
FREEDOMS	-0.5	1.05	383	-0.65	1.05	358	25.1%	0.15 [-0.00, 0.30]			
FREEDOMS II	-0.38	0.97	300	-0.63	1.05	393	25.1%	0.25 [0.10, 0.40]			
SELECT	-0.79	0.83	198	-0.74	0.9	194	24.0%	-0.05 [-0.22, 0.12]			
Total (95% CI)			1487			1241	100.0%	0.05 [-0.14, 0.24]			
Heterogeneity: Tau ² =	= 0.03; Cł	ni² = 18									
Fest for overall effect: Z = 0.49 (P = 0.62)									-0.2 -0.1 0 0.1 0.2 More atrophy in SLDMD More atrophy in PCB		

(B)

	FLDMD PCB							Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
BRAVO	-0.33	0.73	434	-0.58	1.02	225	36.1%	0.25 [0.10, 0.40]	_		
BRAVO	-0.72	0.73	447	-0.58	1.02	225	36.1%	-0.14 [-0.29, 0.01]			
MSCRG	-0.76	0.73	68	-0.7	1.02	72	27.9%	-0.06 [-0.35, 0.23]			
Total (95% CI)			949			522	100.0%	0.02 [-0.26, 0.30]			
Heterogeneity: Tau ²	= 0.05; CI	hi² = 13	3.55, df	-0.2 -0.1 0 0.1 0.2							
Test for overall effec	t: Z = 0.16	6 (P = 0	0.87)	-0.2 -0.1 0 0.1 0.2 More atrophy in FLDMD More atrophy in PCB							

(C)

	S	LDMD		1	РСВ			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
AFFIRM	-0.8	1.31	580	-0.82	1.5	282	26.4%	0.02 [-0.18, 0.22]	+
FREEDOMS	-0.84	1.31	357	-1.31	1.5	331	26.4%	0.47 [0.26, 0.68]	-
FREEDOMS II	-0.86	1.31	264	-1.28	1.5	245	26.1%	0.42 [0.17, 0.67]	
Rinaldi	-1.7	1.31	35	-4.6	1.5	35	21.0%	2.90 [2.24, 3.56]	
Total (95% CI)			1236			893	100.0%	0.85 [0.21, 1.48]	-
Heterogeneity: Tau ² = Test for overall effect:	,			= 3 (P	-2 -1 0 1 2 More atrophy in SLDMD More atrophy in PCB				
			,						wore acopity in Scowb More acopity in PGB

(D)

	FLDMD PCB							Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI
ALLEGRO	-0.87	0.73	550	-1.3	1.3	556	16.5%	0.43 [0.31, 0.55]	-
BRAVO	-1.25	0.73	447	-1.14	1.3	225	15.2%	-0.11 [-0.29, 0.07]	
BRAVO	-0.83	0.73	434	-1.14	1.3	225	15.2%	0.31 [0.13, 0.49]	
COPOLYMER I	-0.6	0.73	14	-1.8	1.3	13	4.2%	1.20 [0.40, 2.00]	
DEFINE	-0.64	0.73	151	-0.81	1.3	163	14.0%	0.17 [-0.06, 0.40]	+ - -
MSCRG	-0.99	0.73	68	-1.22	1.3	72	11.0%	0.23 [-0.12, 0.58]	+
Rinaldi	-3.7	0.73	50	-4.6	1.3	35	8.3%	0.90 [0.42, 1.38]	
TEMSO	-0.39	0.73	358	-0.53	1.3	363	15.8%	0.14 [-0.01, 0.29]	
Total (95% CI)			2072			1652	100.0%	0.30 [0.11, 0.48]	◆
Heterogeneity: Tau ² =	0.05; CI	ni² = 38	3.36, df	= 7 (P	< 0.0	0001);	l² = 82%		-2 -1 0 1 2
Test for overall effect:	Z = 3.11	(P = (0.002)						More atrophy in FLDMD More atrophy in PCB

DMD: Disease Modifying Drug; FLDMD: First-line DMD; SLDMD: Second-line DMD; PCB: Placebo; SD: Standard Deviation.